 |
80 Diseases |  |
201 Trials |
|
201 Trials |  |
5390 News |  |
| «12...56789101112131415...6970» |
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal, HEOR, Real-world evidence, Real-world: Anthracyclines versus No Anthracyclines in the Neoadjuvant Strategy for HER2+ Breast Cancer: Real-World Evidence. (Pubmed Central) - Jul 22, 2023
This study reports real-world evidence showing similar pCR and EFS outcomes with treatment regimens with and without AC and raises awareness of possible overtreatment and long-term toxicity in some patients with HER2+ EBC with the use of AC.
- |||| trastuzumab imbotolimod (BDC-1001) / Bolt Biotherap
New P2 trial, Combination therapy, Metastases: BBI-20231001: Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Jul 20, 2023
P2, N=66, Not yet recruiting, Sponsor: Bolt Biotherapeutics, Inc.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal: Impact of Neoadjuvant Paclitaxel/Trastuzumab/Pertuzumab on Breast Tumor Downsizing for Patients with HER2+ Breast Cancer: Single-Arm Prospective Clinical Trial. (Pubmed Central) - Jul 18, 2023
De-escalated neoadjuvant systemic therapy led to high BCT rates in this cohort. The impact of de-escalated systemic therapy on local therapy and outcomes in early stage HER2+ breast cancer warrants further investigation.
- | AST-302 / Aston Sci., EpiThany
Trial primary completion date, Surgery: Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer (clinicaltrials.gov) - Jul 17, 2023
P2, N=16, Recruiting, Sponsor: University of Washington
The impact of de-escalated systemic therapy on local therapy and outcomes in early stage HER2+ breast cancer warrants further investigation. Trial primary completion date: Jun 2023 --> Oct 2023
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal: Association of Circulating Cardiomyocyte Cell-Free DNA With Cancer Therapy-Related Cardiac Dysfunction in Patients Undergoing Treatment for ERBB2-Positive Breast Cancer. (Pubmed Central) - Jul 14, 2023
P2
Cardiomyocyte cfDNA quantification shows promise as a predictive biomarker to refine risk stratification for CTRCD among patients with breast cancer receiving cardiotoxic cancer therapy, and its use warrants further validation. ClinicalTrials.gov Identifier: NCT02177175.
- | Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial, Combination therapy, Metastases: A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC (clinicaltrials.gov) - Jul 14, 2023
P2, N=78, Recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- | Perjeta (pertuzumab) / Roche
Journal: Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study. (Pubmed Central) - Jul 13, 2023
Our findings support previous data on improved outcomes with the addition of pertuzumab to trastuzumab-based neoadjuvant chemotherapy. This benefit seems to be more significant in patients with clinically positive lymph nodes.
- | Avastin (bevacizumab) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, Trial primary completion date: Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab (clinicaltrials.gov) - Jul 12, 2023
P2, N=120, Active, not recruiting, Sponsor: University of California, Irvine
This benefit seems to be more significant in patients with clinically positive lymph nodes. Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Jun 2023 --> Jun 2024
- ||| HS627 (pertuzumab biosimilar) / Zhejiang Hisun, Perjeta (pertuzumab) / Roche
Trial completion: Comparison of Pharmacokinetics and Safety of HS627(2 Specifications) Versus PERJETA With a Single Injection (clinicaltrials.gov) - Jul 12, 2023
P1, N=180, Completed, Sponsor: Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd
Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Jun 2023 --> Jun 2024 Not yet recruiting --> Completed
- | Opdivo (nivolumab) / Ono Pharma, BMS
Trial completion: Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC) (clinicaltrials.gov) - Jul 12, 2023
P2, N=8, Completed, Sponsor: NYU Langone Health
Not yet recruiting --> Completed Active, not recruiting --> Completed
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Retrospective data, Journal: Efficacy, cardiotoxicity and factors affecting pathologic complete response of neoadjuvant chemotherapy with anthracycline-containing verses anthracycline-free regimens plus dual HER2 blockade for HER2-positive early-stage breast cancer: a retrospective study. (Pubmed Central) - Jul 12, 2023
The TCbHP regimen appears to have lower cardiotoxicity than the AC-THP regimen in terms of LVEF. Mass features and enhancement type at post-NACT MRI significantly associated with the pCR rate of breast cancer patients.
- || Perjeta (pertuzumab) / Roche
☹️ but you’re doing alright still? Going to keep this in mind for Perjeta convo because I feel like I have never seen this laid out so clearly before. @DrSGraff does the article discuss long-term effects? (Twitter) - Jul 10, 2023
- || Perjeta (pertuzumab) / Roche
Seeing those effects of pertuzumab laid out graphically🔥 (thank you) (Twitter) - Jul 10, 2023
- | Enrollment open: Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE) (clinicaltrials.gov) - Jul 6, 2023
P2, N=240, Recruiting, Sponsor: German Cancer Research Center
Mass features and enhancement type at post-NACT MRI significantly associated with the pCR rate of breast cancer patients. Not yet recruiting --> Recruiting
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Retrospective data, Review, Journal: Pathologic Complete Response Achieved in Early-Stage HER2-Positive Breast Cancer After Neoadjuvant Therapy With Trastuzumab and Chemotherapy vs. Trastuzumab, Chemotherapy, and Pertuzumab: A Systematic Review and Meta-Analysis of Clinical Trials. (Pubmed Central) - Jul 3, 2023
This would result in achieving a better pCR. And by improving pCR rates, the survival outcomes of patients can be significantly improved.
- | Avastin (bevacizumab) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Trial completion date, Trial primary completion date: Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab (clinicaltrials.gov) - Jul 3, 2023
P2, N=120, Active, not recruiting, Sponsor: University of California, Irvine
And by improving pCR rates, the survival outcomes of patients can be significantly improved. Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2021 --> Jun 2023
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Retrospective data, Review, Journal, Metastases: Identifying the optimal therapeutics for patients with hormone receptor-positive, HER2-positive advanced breast cancer: a systematic review and network meta-analysis. (Pubmed Central) - Jul 3, 2023
Prominent status of dual-targeted therapy for patients with HR+/HER2+ metastatic breast cancer was revealed. Compared with chemotherapy-containing regimens, the ET-containing ones showed better efficacy and similar safety profiles, which could be recommended in clinical practice.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment change: BOLD-1: Adjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer (clinicaltrials.gov) - Jun 27, 2023
P3, N=516, Active, not recruiting, Sponsor: Helsinki University Central Hospital
Compared with chemotherapy-containing regimens, the ET-containing ones showed better efficacy and similar safety profiles, which could be recommended in clinical practice. N=1366 --> 516
- | Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
Journal, Metastases: Impact of Pertuzumab and Ado-Trastuzumab Emtansine on Cumulative Avoidance of Recurrence Among Women Treated for Locally Advanced, Inflammatory, or Early-Stage Nonmetastatic HER2-Positive Breast Cancer in the United States. (Pubmed Central) - Jun 26, 2023
Our results suggest that utilization of HER2-targeted treatments in the US has the potential to change the epidemiology of HER2-positive EBC by preventing a substantial number of women from experiencing disease recurrence. These improvements may help to inform our understanding of the future disease and economic burden of HER2-positive BC in the US.
- | Trial initiation date, Metastases: Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - Jun 26, 2023
P2, N=25, Not yet recruiting, Sponsor: Mayo Clinic
These improvements may help to inform our understanding of the future disease and economic burden of HER2-positive BC in the US. Initiation date: Apr 2023 --> Sep 2023
- |||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Clinical: Any guidelines/articles on Herceptin and Perjeta on patients with existing Autoimmune diseases? (Twitter) - Jun 25, 2023
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New trial: BiOnHER: Early On-treatment Transcriptional Profiling as Predictor of Response in Early-stage HER2-positive Breast Cancer (clinicaltrials.gov) - Jun 22, 2023
P=N/A, N=80, Recruiting, Sponsor: Institut Catal
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal: Enhanced binding at fever temperatures of HER2 in complex with trastuzumab and pertuzumab. (Pubmed Central) - Jun 20, 2023
Initiation date: Apr 2023 --> Sep 2023 Trastuzumab and pertuzumab present the highest binding
- | Perjeta (pertuzumab) / Roche
Journal: BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer. (Pubmed Central) - Jun 20, 2023
In patients with HER2-type or HER2-single-type tumors, pertuzumab significantly improved the pCR rate and decreased the risk of breast cancer mortality, which was not observed in other subtypes. BluePrint subtyping may be valuable in future studies to identify patients that are likely to be highly sensitive to HER2-targeting agents.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal: Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab. (Pubmed Central) - Jun 19, 2023
The results of this diagnostic/prognostic study suggest that the HER2DX pCR score assay could predict pCR following treatment with deescalated neoadjuvant paclitaxel with trastuzumab and pertuzumab in patients with early-stage ERBB2+ BC. The HER2DX pCR score might guide therapeutic decisions by identifying patients who are candidates for deescalated or escalated approaches.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Retrospective data, Journal: Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab. (Pubmed Central) - Jun 19, 2023
This diagnostic/prognostic study demonstrated that the genomic assay predicted pCR following neoadjuvant trastuzumab-based chemotherapy with or without pertuzumab. This assay could guide therapeutic decisions regarding the use of neoadjuvant pertuzumab.
- || Review, Journal, EGFR exon 20: New therapies in non-small cell lung cancer with EGFR exon 20 insertion mutations. (Pubmed Central) - Jun 19, 2023
However, therapies were assessed in single-arm CTs with low-quality evidence. Comparative studies with more extensive patient follow-up, larger sample size and better design are needed to reliably quantify the effect of these drugs.
- | Trial completion date, Trial primary completion date: Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE) (clinicaltrials.gov) - Jun 18, 2023
P2, N=240, Not yet recruiting, Sponsor: German Cancer Research Center
Comparative studies with more extensive patient follow-up, larger sample size and better design are needed to reliably quantify the effect of these drugs. Trial completion date: Dec 2029 --> Dec 2030 | Trial primary completion date: Apr 2029 --> Mar 2030
- | Trial completion date, Trial primary completion date, Metastases: SU2C ACT3: Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer (clinicaltrials.gov) - Jun 18, 2023
P3, N=500, Recruiting, Sponsor: Massachusetts General Hospital
Trial completion date: Dec 2029 --> Dec 2030 | Trial primary completion date: Apr 2029 --> Mar 2030 Trial completion date: Feb 2023 --> Apr 2026 | Trial primary completion date: Feb 2022 --> Apr 2025
- | Enrollment open: Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer (clinicaltrials.gov) - Jun 18, 2023
P2, N=185, Recruiting, Sponsor: Baylor Breast Care Center
Trial completion date: Feb 2023 --> Apr 2026 | Trial primary completion date: Feb 2022 --> Apr 2025 Not yet recruiting --> Recruiting
- ||||| Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Enrollment closed, Monotherapy: DESTINY-Breast11: Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer (clinicaltrials.gov) - Jun 18, 2023
P3, N=644, Active, not recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche, Tecentriq (atezolizumab) / Roche
Enrollment closed, Combination therapy, Metastases: KATE3: A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC) (clinicaltrials.gov) - Jun 18, 2023
P3, N=96, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| lapatinib / Generic mfg., Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Session 2 Integration of anti Her2 with radiation The concomitant administration of trastuzumab, pertuzumab and lapatinib with RT(intracranial or extracranial)is safe! @OncoAlert #florencebreast23 @acampsmalea @MartaPerachino @ChelainG @FrancicaPaola @FatjonaKrajaMD (Twitter) - Jun 16, 2023
- || Review, Journal: Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases. (Pubmed Central) - Jun 16, 2023
The results of this meta-analysis, comprising the limited data available, suggest that intrathecal administration of HER2-targeted therapy for patients with HER2+ BC LM confers no additional benefit over oral and/or IV treatment regimens. Although the number of patients receiving trastuzumab deruxtecan in this cohort is small, this novel agent offers promise for this patient population and requires further investigation in prospective studies.
- |||| lapatinib / Generic mfg., Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Anti Her2 therapy : Integration with RT is safe for trastuzumab, pertuzumab and lapatinib both intra and extracranially 🤗 #FlorenceBreast23 @OncoAlert @Icro_Meattini @matteolambe @weoncologists @Dr_m_garousi @ChelainG @MartaPerachino @FrancicaPaola @FatjonaKrajaMD (Twitter) - Jun 16, 2023
- | Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma, Perjeta (pertuzumab) / Roche
Enrollment closed: Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer (clinicaltrials.gov) - Jun 15, 2023
P2, N=20, Active, not recruiting, Sponsor: Mayo Clinic
Although the number of patients receiving trastuzumab deruxtecan in this cohort is small, this novel agent offers promise for this patient population and requires further investigation in prospective studies. Recruiting --> Active, not recruiting
- ||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Clinical: Hot off the press from @ASCO #TAPUR Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study https://t.co/ilNcPYdV8U (Twitter) - Jun 14, 2023
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche, Tecentriq (atezolizumab) / Roche
Trial primary completion date, Combination therapy: Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC (clinicaltrials.gov) - Jun 13, 2023
P2, N=33, Active, not recruiting, Sponsor: Nancy Lin, MD
Recruiting --> Active, not recruiting Trial primary completion date: Jul 2023 --> Aug 2024
- | Journal: Therapeutic advances in HER2+ breast cancer (Pubmed Central) - Jun 12, 2023
In the localized stage, neoadjuvant chemotherapy associated with trastuzumab is now the standard strategy, allowing the adjuvant strategy to be adapted to the therapeutic response, with the use of another ADC, T-DM1, in the absence of pathological complete response. These various therapeutic advances have led to a significant improvement in the prognosis of HER2-positive breast cancer, whether at the metastatic or localized stage.
- | Perjeta (pertuzumab) / Roche
Journal, Metastases: Pertuzumab as second? or later?line therapy for human epidermal growth factor receptor 2?positive metastatic breast cancer: A clinical experience. (Pubmed Central) - Jun 12, 2023
In conclusion, the median overall survival of patients who underwent second- or later-line pertuzumab treatment was similar to that reported for patients who underwent first-line pertuzumab treatment, and the safety profile was acceptable. These data support the use of pertuzumab for second- or later-line therapy when it was not administered as first-line therapy.
- | Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Herceptin (trastuzumab) / Roche
New P2 trial: ARIADNE: Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer (clinicaltrials.gov) - Jun 12, 2023
P2, N=370, Not yet recruiting, Sponsor: Karolinska University Hospital
- ||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Clinical: Subcutaneous delivery of fixed-dose adjuvant pertuzumab + trastuzumab proved to have favorable tolerability, w/ a safety profile consistent with that seen with intravenous delivery of the regimen in pts w/ HER2+ breast cancer. @BCJoyceO #bcsm #oncology https://t.co/zuHJlfdCLv (Twitter) - Jun 11, 2023
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal: Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer. (Pubmed Central) - Jun 11, 2023
These data support the use of pertuzumab for second- or later-line therapy when it was not administered as first-line therapy. HER2DX pCR-score and risk-score might help identify ideal candidates to receive neoadjuvant dual HER2 blockade in combination with a single taxane in early-stage HER2+ breast cancer.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open: EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer (clinicaltrials.gov) - Jun 8, 2023
P3, N=1406, Recruiting, Sponsor: Fudan University
HER2DX pCR-score and risk-score might help identify ideal candidates to receive neoadjuvant dual HER2 blockade in combination with a single taxane in early-stage HER2+ breast cancer. Not yet recruiting --> Recruiting
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial: Short-course Trastuzumab, Pertuzumab With Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer (clinicaltrials.gov) - Jun 7, 2023
P2, N=125, Not yet recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
- ||| Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Enrollment closed, Trial completion date, Combination therapy, Metastases: DESTINY-Breast07: A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer (clinicaltrials.gov) - Jun 7, 2023
P1b/2, N=245, Active, not recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Jul 2025
- |||| Trial completion, Tumor mutational burden, Metastases: My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Jun 7, 2023
P2a, N=670, Completed, Sponsor: Genentech, Inc.
Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Jul 2025 Active, not recruiting --> Completed
- | Perjeta (pertuzumab) / Roche
Retrospective data, Journal: Efficacy and safety of treatment with or without pertuzumab for HER2-positive breast cancer: A meta-analysis. (Pubmed Central) - Jun 6, 2023
Active, not recruiting --> Completed These results support that the treatment in combination with pertuzumab is superior to the treatment in combination without pertuzumab in the treatment of HER2-positive breast cancer, but there are some adverse effects such as diarrhea, anemia, and rash, which should be carefully monitored in clinical practice.
- | Perjeta (pertuzumab) / Roche
Journal: Combined physicochemical and functional assessment of pertuzumab integrity supports extended in-use stability. (Pubmed Central) - Jun 5, 2023
These results support that the treatment in combination with pertuzumab is superior to the treatment in combination without pertuzumab in the treatment of HER2-positive breast cancer, but there are some adverse effects such as diarrhea, anemia, and rash, which should be carefully monitored in clinical practice. The herein presented data showed that the ready-to-use infusion solutions stored at 4?
- ||||| zanidatamab (ZW25) / Jazz, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Clinical: 🆕HERIZON-BTC-01 study: Zanidatamab in previously-treated 🎯#HER2‑amplified biliary tract cancer (BTC) @DrShubhamPant Again gallbladder ca >1/2 of these cases. #ASCO23 @OncoAlert HER2➕in cholangiocarcinoma needs approvals. @NCCN only trastuzumab/pertuzumab. No @FDAOncology. (Twitter) - Jun 2, 2023